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ARTICLE
Homozygous MTAP deletion in primary human
glioblastoma is not associated with elevation of
methylthioadenosine
Yasaman Barekatain 1,2,3✉, Jeffrey J. Ackroyd1,3, Victoria C. Yan 1,3, Sunada Khadka1,2,3, Lin Wang4,
Ko-Chien Chen2,3, Anton H. Poral1, Theresa Tran1, Dimitra K. Georgiou 1, Kenisha Arthur1, Yu-Hsi Lin1,
Nikunj Satani 1, Elliot S. Ballato 1, Eliot I. Behr 1,2, Ana C. deCarvalho 5, Roel G. W. Verhaak6,
John de Groot7, Jason T. Huse8, John M. Asara9, Raghu Kalluri 2 & Florian L. Muller 1,10✉
Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as
glioblastoma represents a potentially targetable vulnerability. Homozygous MTAP-deleted
cell lines in culture show elevation of MTAP’s substrate metabolite, methylthioadenosine
(MTA). High levels of MTA inhibit protein arginine methyltransferase 5 (PRMT5), which
sensitizes MTAP-deleted cells to PRMT5 and methionine adenosyltransferase 2A (MAT2A)
inhibition. While this concept has been extensively corroborated in vitro, the clinical rele-
vance relies on exhibiting significant MTA accumulation in human glioblastoma. In this work,
using comprehensive metabolomic profiling, we show that MTA secreted by MTAP-deleted
cells in vitro results in high levels of extracellular MTA. We further demonstrate that
homozygous MTAP-deleted primary glioblastoma tumors do not significantly accumulate
MTA in vivo due to metabolism of MTA by MTAP-expressing stroma. These findings
highlight metabolic discrepancies between in vitro models and primary human tumors that
must be considered when developing strategies for precision therapies targeting glioblastoma
with homozygous MTAP deletion.
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Genomic deletions of tumor-suppressor genes are prevalentdrivers of tumor progression in various cancers, but theirtherapeutic inaccessibility subverts their potential use via
precision oncology. Such deletion events often confer less-obvious
genetic vulnerabilities that may be therapeutically exploited by
identifying their metabolic consequences1,2. Homozygous dele-
tion of CDKN2A/B at the 9p21 chromosome is an early clonal
event in tumorigenesis3 that is homogeneously distributed in
glioblastoma multiforme (GBM), pancreatic adenocarcinoma,
and lung cancer4. Within the context of GBM, homozygous 9p21
deletions are found in around 30–50% of all cases5. Of particular
interest in developing therapies that capitalize on aberrant tumor
metabolism is collateral deletion of the evolutionarily conserved
metabolic enzyme methylthioadenosine phosphorylase (encoded
by MTAP). Owing to the proximity of MTAP to the CDKN2A
tumor-suppressor locus6,7, co-deletion of MTAP may be observed
in 80–90% of all tumors harboring homozygous deletion of
CDKN2A8 (Supplementary Fig. 1). The ubiquity of this event
alongside the poor prognosis of cancers such as GBM has urged
the development of novel therapies that capitalize on downstream
vulnerabilities conferred by MTAP deletion.
In addition to its broader role in polyamine biosynthesis,
MTAP is critically involved in the salvage pathways of both
methionine and adenine, catalyzing the conversion of methyl-
thioadenosine (MTA) to S-methyl-5-thio-D-ribose-1-phosphate
(Fig. 1a). Cancers sustaining homozygous MTAP deletions are
thus expected to accumulate MTA; extensive in vitro evidence in
diverse cancer cell lines supports this logic9,10 (though methio-
nine and cysteine availability in media also influences MTA
levels11). Efforts to act on this intriguing metabolic phenotype
have identified the inhibitory effect of excess MTA on protein
arginine methyltransferase 5 (PRMT5), a key regulator of tran-
scription. PRMT5 exerts its regulatory effects when conjugated
with WD repeat-containing protein (WDR77) to generate what is
known as the methylosome12–14. High levels of MTA act as an
endogenous inhibitor of PRMT5 activity, thereby hindering
methylosome formation and sensitizing cells to reduced levels of
PRMT5 and WDR77. Therapeutic targeting of PRMT5 in
homozygousMTAP-deleted cancer cells has thus been considered
a promising strategy to prevent methylosome organization,
selectively killing cancer cells9,10,15 (Supplementary Fig. 1).
Another approach leverages the relationship between PRMT5 and
S-adenosylmethionine (SAM)9,16,17. SAM is the natural substrate
of PRMT5, and MTA is a substrate-competitive inhibitor of
PRMT5. Lowering levels of SAM would thus exacerbate the
inhibitory effect of elevated MTA. Accordingly, inhibition of
methionine adenosyltransferase 2A (MAT2A), which generates
SAM, has also been considered as a potential therapeutic target in
homozygousMTAP-deleted cancers9,16,17 (Supplementary Fig. 1),
and this strategy has progressed to an ongoing phase I trial
(NCT03435250).
Both of the aforementioned therapeutic approaches are pre-
dicated on the presence of exceedingly high MTA levels in
MTAP-deleted cancer cells compared to MTAP-intact tissues.
While it may seem natural that homozygous MTAP-deleted
primary human tumors should also display this phenotype, recent
reports identifying this intriguing vulnerability have not mea-
sured MTA levels in primary human tumors9,10,18. We could not
find any previous studies that reported MTA measurements in
actual primary human tumors as a function of the MTAP
genotype.
In this study, we found that highly elevated MTA levels found
in MTAP-deleted glioma cell lines in culture cannot be extra-
polated to primary GBMs. Our series of metabolomic studies in
cell culture and primary tumors demonstrate that MTA accu-
mulation in culture is most evident extracellularly, reflecting
secretion of MTA byMTAP-deleted cells. Building on this finding
in primary tumors, our data strongly suggest that the abundance
of non-malignantMTAP wild-type (WT) stromal cells metabolize
the secreted MTA from the homozygous MTAP-deleted GBM
cells. As the promise of synthetic therapies that are lethal against
homozygous MTAP-deleted cancers is dependent on intracellular
accumulation of MTA, our data caution against the expedient
translation of the MTAP-deletion-targeted precision therapies to
the clinic and strongly contend that more research is needed into
the fundamental metabolic differences between model systems
and primary tumors.
Results
Secretion of MTA by MTAP-deleted cells in culture. By ana-
lyzing multiple metabolic profiling studies using independent
metabolomic platforms, we observed a discrepancy between
reported intracellular MTA levels in homozygous MTAP-deleted
cells9,19–25, even within the same cell lines (Supplementary
Fig. 2a, b). This discrepancy can be attributed to the extent to
which these studies distinguish between intracellular and extra-
cellular distribution—which depends on how extensively the cells
were washed before metabolite extraction. For instance, in the
NCI-60 profiling study by Ortmayr et al.22, which focused
exclusively on intracellular metabolites (extensive washing of cell
pellets with minimal residual media), there was no statistically
significant increase in MTA levels in MTAP-deleted compared to
WT cancer cell lines (Supplementary Fig. 2a). However, a colla-
boration between Metabolon, Inc. and the NCI using the NCI-60
panel26 did not specify whether the cell pellet was washed and
reported a threefold increase in MTA inMTAP-deleted compared
to MTAP-WT cell lines (Supplementary Fig. 2b). In contrast to
intracellular levels of MTA, re-analysis of one notable study that
conducted mass spectrometry (MS) profiling of conditioned
media (secreted metabolites) showed >100-fold increases in MTA
in MTAP-deleted cell lines compared to intact cell lines (Sup-
plementary Fig. 2c; for comparison with lactate, see Supplemen-
tary Fig. 2d)27. The micromolar extracellular levels of MTA
reported by these studies sharply contrasts the nanomolar to
picomolar levels of MTA typically found in conditioned media of
MTAP-WT cells24,28. Also, direct measurement of MTA secretion
from MTAP-deleted cells into culture medium showed a sig-
nificantly higher rate of secretion from MTAP-deleted cell lines
than from MTAP-WT lines19,29.
To independently investigate the likelihood of MTA’s pre-
dominant presence in conditioned media from MTAP-deleted
cells, we performed mass spectroscopy on cell pellets and corre-
sponding conditioned media (Fig. 1b) from the panel of cell lines
with verified MTAP status (Fig. 1c and Supplementary Fig. 3).
First, we compared MTA levels from the intracellular and
extracellular environments of three MTAP-deleted glioma cell
lines (U87, Gli56, and SW1088) with MTAP-WT cell lines
(Fig. 1d, e). We observed dramatic increases in MTA levels in
conditioned media of MTAP-deleted versus WT cell lines but a
much more modest increase of MTA levels in the cell pellets of
these respective cell lines. The significant differences in
extracellular MTA between MTAP-deleted and WT compared
to the minor differences in intracellular MTA levels of the same
cells indicate that MTAP-deleted cells secrete MTA (Fig. 1d
versus Fig. 1e). To corroborate our findings, we also performed a
time-course experiment for MTAP-deleted and MTAP-WT cell
lines. Although a time-dependent increase in MTA was apparent
in both the cell pellets and conditioned media, the increase was
exacerbated in the extracellular profile (Fig. 1f). Comparison of
intracellular and extracellular levels of MTA and SAM demon-
strated the tight regulation of intracellularly retained versus
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secreted metabolites (Fig. 1f versus Fig. 1g). We further measured
the absolute amount (nanomoles) of MTA for a paired sample of
cell pellets and conditioned media. Figure 1h indicates that the
amount of MTA recovered from the conditioned media from
MTAP-deleted cells cultured for 3 days is approximately 200
times more than MTA recovered from the cell pellets. This is in
sharp contrast with the MTAP-WT cells, where a comparable
amount of MTA was recovered from media (extracellular) and
the cell pellet (intracellular). Taken together, our findings agree
with previous conclusions 19,29 that homozygous MTAP-deleted
cells secret MTA resulting in significant extracellular accumula-
tion of MTA.
Fig. 1 Dramatic elevation of MTA in conditioned medium ofMTAP-deleted cells versus WT coupled with mild intracellular elevation. a The methionine
salvage pathway (based on KEGG68) with most genes are housekeeping expressed broadly across cell lines and tissues (DepMap, The Human Protein
Atlas). SAM S-adenosylmethionine, dcSAM S-adenosylmethionineamine, MTA methylthioadenosine, SPD spermidine, PTN putrescine, MTOB 4-
methylthio-2-oxobutanoate, DMTP 1,2-dihydroxy-5-(methylthio)pent-1-en-3-one, MTP 3-(methylthio)propanoate, MTDO-P 5-(methylthio)-2,3-
dioxopentyl-phosphate, MTRi-P S-methyl-5-thio-D-ribulose-1-phosphate, 5-MTR-P methylthioribose-1-phosphate. b MTA levels were determined in
conditioned media (extracellular) and washed cell pellets (intracellular) of homozygous MTAP-deleted (MTAP−) and wild-type (MTAP+) cells in culture.
Color coding reflects the same cell line for pellet/media. c MTAP status of cell lines confirmed by western blot repeated independently twice. d, e Levels of
MTA (mean+ SD, N= 3 biological replicates) in a panel of glioma cell; washed cell pellet—intracellular (d) and conditioned media—extracellular (e). Note
>200-fold increase in MTA in conditioned media ofMTAP-deleted versus intact cell lines (***p= 0.0005, unpaired two-tailed Student’s t test with unequal
variance), while only marginal elevations are seen for this comparison in the cell pellet. f, g Time course of MTA levels in cell pellet and conditioned media
(f) with SAM shown for comparison (g). x-axis: time of harvest after last media change; y-axis: ion counts for each metabolite. Each bar represents one
biological replicate. There was a distinct, time-dependent increase in MTA in media ofMTAP-deleted cells with a modest increase of MTA in the cell pellet.
There was an imbalance of MTA in the pellet versus the media, contrasting what was observed with SAM, which is exclusively intracellular. h Absolute
quantification of MTA in cell pellet and conditioned media (mean+/− SD, N= 3 biological replicates). The amount of MTA recovered from conditioned
media of MTAP-deleted cells is 200-fold greater than recovered from the cell pellets. In contrast, in MTAP-WT cells, the amount of MTA in conditioned
media is comparable to that in cell pellet. The modest intracellular accumulation of MTA (sixfold) in the MTAP-deleted cells compared to the WT cells is
overshadowed by the increase of extracellular MTA. Significant values are indicated as ****p= 4 × 10−8, ***p= 0.00006, @@@@p= 10−12, and %p= 0.02
using multiple t test with Bonferroni correction.
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No significant elevation of MTA in homozygousMTAP-deleted
human GBMs. While elevated MTA levels in vitro clearly define a
promising actionable metabolic vulnerability, none of the
studies9,10,15,18 reported on the critical question of whether
homozygous MTAP-deleted primary human tumors faithfully
replicate the elevation of MTA observed in vitro. In other words,
does the metabolic vulnerability mediated by homozygous MTAP
deletion hold in primary human tumors, including GBM? To
answer this question directly, using our metabolomic profiling data
generated with the BIDMC platform, we compared MTA levels
between resected human GBM tumors with verifiedMTAP-deletion
status30–32 (Fig. 2a, b). This is the first study to address MTAP
deletion’s effects on MTA levels in human tumors. Figure 2c shows
that, in 17 GBM tumors (HF series), MTA levels do not differ
significantly between homozygousMTAP-deleted andMTAP-intact
tumors (~1.4-fold higher median MTA levels in MTAP-deleted
tumors; p= 0.20, unpaired 2-tailed t test with unequal variance).
When corrected for loading, the median MTA levels were only 1.2-
fold higher in MTAP-deleted than in MTAP-intact tumors (p=
0.09; Fig. 2d). Next, we normalized MTA levels to SAM levels for
each tumor to account for the methionine salvage pathway’s
upregulation (Fig. 2e). Since the levels of SAMwere not significantly
different between MTAP-deleted and MTAP-WT cells in culture15
(data replotted in Supplementary Fig. 4), SAM is a suitable meta-
bolite for normalization purposes. When the MTA levels were
corrected to SAM levels in primary human GBM tumors, the dif-
ference between MTAP-deleted and MTAP-intact tumors became
decisively nonsignificant (1.1-fold higher median MTA levels in
MTAP-deleted tumors; p= 0.24; Fig. 2e). This result runs contrary
to the expected phenotype in homozygous MTAP-deleted cells in
culture. This nonsignificant MTA elevation pales further compared
to outliers driven by specific genetic events that fully recapitulate
metabolic data recorded intracellularly in cell culture, such as the
>100-fold increase in the levels of 2-hydroxyglutarate (2-HG),
driven by the point mutation of IDH1 (Fig. 2f).
To further confirm the discrepancy in MTA levels in human
GBM tumors and cells in culture, we measured MTA levels in a
different set of tumors (MDA series) using a different
metabolomic platform (Metabolon, Inc.). The MTAP status of
tumors was confirmed by immunohistochemistry using a
validated MTAP antibody. Consistent with findings from Fig. 2,
we did not observe a statistically significant increase in MTA
levels between MTAP-deleted and intact human GBM tumors
(Supplementary Fig. 5), confirming the discrepancies between the
in vitro models and primary human GBM tumors.
We further sought to test our conclusions by interrogating
independent GBM metabolomic datasets in the literature, though
we could not find any for which genomic information was also
available. Metabolomic analyses of primary human GBM tumors
are sparsely reported in the literature. The few studies that have
been conducted have favored comparison between tumor
populations at different stages or grades, rather than considering
the unique metabolic landscape of individual tumors33–37.
Supplementary Fig. 6a–f shows the MTA levels among 50 human
GBM tumors sorted based on MTAP mRNA levels (data obtained
from Supplementary Information of Prabhu et al.38). The
frequency of homozygous MTAP deletion in GBM can reach
50%39–41. Based on an analysis of The Cancer Genome Atlas
(TCGA)-GBM tumor42,43 where both mRNA and genomic copy
numbers were available, we find that, despite some exceptions, the
majority of homozygous MTAP-deleted tumors fall in the two
lower quartiles of MTAP expression (Supplementary Fig. 6g). We
thus posit that, for data shown in Supplementary Fig. 6a–f,
the two lower quartiles of MTAP mRNA expression would
include most homozygous MTAP-deleted tumors, while the
majority of tumors in the third and fourth quartiles would be
those that are MTAP-intact. The comparison of MTA levels
between quartiles is statistically insignificant (p= 0.48, single-
factor analysis of variance), which agrees with our conclusion that
MTAP-deleted tumors do not show selective elevation of MTA.
We next interrogated another human glioma metabolomic
profiling dataset from Chinnaiyan et al.44 (Supplementary Fig. 7),
where again no genomic data for individual tumors were
available, which would have allowed us to determine MTAP-
deletion status. Thus, we sought to match the metabolomic data
for different glioma grades with the reported frequency of MTAP
deletions in them. The frequency of homozygous
CDK2NA/MTAP deletion is <3% in grade 2 glioma and <10%
in grade 2/3 glioma30, sharply contrasting the frequency of
homozygous MTAP deletion, which is as high as 50% in grade 4
glioma (GBM)5,39,41. Thus, we would expect that the elevation of
MTA would correspond to this deletion frequency pattern
according to tumor grade, with higher MTA levels in GBM and
considerably lower levels in grade 2 glioma. However, despite
these different frequencies of MTAP deletion, MTA levels were
similar in grade 2, grade 3, and grade 4 (GBM) tumors (p= 0.15,
single-factor analysis of variance, Supplementary Fig. 7a, b).
Importantly, no extreme outliers in MTA were evident. Even the
highest MTA levels in individual GBM cases were about twofold
higher than the median MTA levels of lower-grade glioma
tumors. These data starkly contrast the extreme elevations in 2-
HG levels, driven by IDH mutations in gliomas; these elevations
were frequent in grade 2 and 3 gliomas but infrequent in GBM
(Supplementary Fig. 7c, d). In addition to these MS metabolomic
studies, nuclear magnetic resonance (NMR) high-resolution
magic-angle spinning (HR-MAS) metabolomic profiles of GBM
on a large scale (n > 100 cases) have not detected MTA in MTAP-
deleted tumors even though HR-MAS can usually detect
metabolites at a minimum concentration of 1 µM45. That MTA
could still not be detected in these contexts suggests that <1 µM
MTA is present in GBM tumors, which supports our conclusion
that there are no glioma tumors, regardless of MTAP deletion
status, with extreme elevations in MTA. We conclude that
homozygous MTAP-deleted primary GBM tumors do not
selectively exhibit significant elevation of MTA as opposed of
what was reported in vitro, a conclusion supported by both our
own results and corroborated by public domain data.
The statistically insignificant elevation of MTA (1.4-fold in
absolute MTA levels, and less when correcting for total load and
SAM levels) in human GBM tumors is at odds with the multiple-
fold-change MTA elevations reported in vitro. Metabolomic data
for MTA levels in human tumors are the measure of both
intracellular and extracellular MTA. In cell culture, empirical
observations indicate that differences in MTA levels between
MTAP-deleted and WT cells are most evident in the extracellular
rather than intracellular environment (Fig. 1). While we cannot
distinguish intracellular and extracellular MTA in primary
tumors, we can investigate the effects of MTAP deletion in
primary tumors on intracellular PRMT5 activity inhibition.
PRMT5 mediates the formation of symmetric dimethylarginine
(SDMA); thus, the PRMT5 activity can be assessed by measuring
the SDMA levels using the antibody against an SDMA. First, we
measured the SDMA levels in MTAP-WT and MTAP-deleted
cancer cells in culture (under the same conditions in which we
measured MTA accumulation in media) by western blot analysis
(Supplementary Fig. 8). As expected, the SDMA levels were lower
in MTAP-deleted cells than MTAP-WT, indicating partial
inhibition of PRMT5. Also, SDMA levels decreased following
MTA treatment (50 and 100 μM). These two data pieces
recapitulate the literature and support the antagonistic relation-
ship between PRMT5 activity and MTA levels. Then we measured
the SDMA levels inside human GBM tumors using the same
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antibody (Fig. 2g). Unlike cell culture experiments, primary
tumors showed no meaningful decrease in levels of SDMA,
representing PRMT5 activity, in homozygous MTAP-deleted
compared to MTAP-intact human GBM tumors. These data are
consistent with the marginal elevation of MTA, intracellular or
extracellular, in MTAP-deleted tumors. While we did not find a
correlation between SDMA levels and tumors’ MTAP status, we
noticed some variation in SDMA levels between tumors
regardless of their MTAP status. Unlike cells in culture,
homozygous MTAP-deleted GBM tumors express non-zero
MTAP levels in western blot (Fig. 2g). This is because human
GBM tumors are comprised of a mix of malignant glioma
Fig. 2 No significant elevation of MTA and no specific inhibition of PRMT5 activity in homozygousMTAP-deleted primary resected GBM tumors. a GBM
tumors (heterogeneous mix of transformed glioma cells and non-malignant stroma) of defined MTAP-deletion status (genomic profiling from Kim et al.31)
were evaluated by mass spectrometry for MTA levels and western blot for SMDA. b Genomic copy-number data (dark blue: homozygous deletion, dark
red: amplification) around the 9p21 locus. Each strip in the y-axis represents a single tumor at the specific chromosomal location (x-axis). c MTA levels in
homozygous MTAP-deleted (MTAP−) versus MTAP-intact (MTAP+) GBM tumors, using the BIDMC mass spectrometric platform. Each bar represents
MTA levels for each tumor (N= 1). There is a 1.4-fold increase in the median MTA levels (absolute ion counts) in MTAP-deleted tumors compared to
intact tumors (p= 0.20, unpaired 2-tailed t test with unequal variance). d, e Same data but expressed normalized to total ion count for sample loading
normalization (d) and as a ratio to SAM levels to account for methionine salvage pathway activity (e). Regardless of normalization, no significant elevation
of MTA inMTAP-deleted tumors was evident. In contrast, f tumors with IDH1mutation stand out by their dramatic elevation of 2-hydroxyglutarate (2-HG),
providing a positive control for genomic/metabolic correlation. g To evaluate PRMT5 activity, GBM tumor lysates were immunoblotted for SDMA,
repeated once. As a positive control, we assessed SDMA levels in MTAP-deleted U87 glioma cells in culture, alone or treated with exogenous MTA versus
MTAP-reconstituted (U87-MTAP) cells. SDMA levels were lower in U87 than in U87-MTAP cells, indicating partial inhibition of PRMT5. SDMA levels
further decreased following MTA treatment. Unlike in cultured cells, no specific decrease in SDMA levels was observed in MTAP-deleted versus intact
GBM tumors. The presence of myeloid cells in a tumor is confirmed by the myeloid marker IBA1 in tumor lysates but not seen in cells in culture. h MTAP
protein levels corrected for loading with GAPDH control (samples derive from the same experiment and gels were processed in parallel). Due to the
presence of non-malignant MTAP-expressing cells in the lysate of whole tumors, MTAP protein levels are not zero for homozygousMTAP-deleted tumors;
however, on average, they have lower MTAP protein levels compared to intact tumors.
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(cancer) cells with genetic alterations like homozygous MTAP-
deletion and non-transformed non-malignant stromal cells (e.g.,
myeloid cells). Thus, in homozygous MTAP-deleted tumors, only
malignant glioma cells lack MTAP, while stromal cells express
normal levels. Such non-malignant MTAP-expressing cells drive
the non-zero MTAP expression (mRNA or western blot) in bulk
homozygous MTAP-deleted GBM tumors. However, on average,
theMTAP-deleted tumors express a lower (but non-zero) amount
of MTAP protein levels by the western blot than MTAP-intact
(Fig. 2h). The presence of myeloid cells (microglia/macrophages)
in a tumor is confirmed by the myeloid marker IBA1 in a western
blot of tumor lysates but not seen in cells in culture (Fig. 2g). All
tumors show some levels of IBA1, verifying myeloid stromal
infiltration. IBA1 levels in MTAP-deleted tumors nicely correlate
with residual MTAP levels—i.e., the homozygous MTAP-deleted
HF3174 tumor has the lowest IBA1 compared to other
homozygous MTAP-deleted tumors, which also expresses the
lowest but non-zero MTAP levels.
Stromal infiltration drives the in vitro/in vivo discordance in
MTA. We next sought to identify the cause of discordance in
MTA levels between cells in culture and human GBM
tumors. Previous work by Sanderson et al.11, showed that MTAP-
deleted cells accumulate less amount of MTA when cultured in
restricted methionine (3 μM) or cysteine (6 μM) RPMI than when
cultured in the standard formulation with 100 μM methionine
and 200 μM cysteine (data replotted in Supplementary Fig. 9).
Motivated by this study, we sought to investigate the effects of
culturing cells in physiological media on intracellular and extra-
cellular levels of MTA . The composition of physiological media
better represents the concentration of metabolites in human
plasma46 (Supplementary Fig. 10a). Thus, we cultured MTAP-
deleted and WT cells in Dulbecco’s Modified Eagle’s medium
(DMEM; historic medium) and Plasmax (physiological medium)
supplemented with 2.5% fetal bovine serum (FBS) and compared
the levels of MTA in the cell pellet and conditioned media.
Supplementary Fig. 10b, c shows no significant difference
between average MTA levels of MTAP-deleted cells cultured in
DMEM versus Plasmax, either extracellular or intracellular.
Supplementary Fig. 10d indicates that, just like in DMEM, the
MTA levels are highly elevated in conditioned media of MTAP-
deleted versus intact cells, while most modest elevations were
evident in the cell pellets . These data indicate that, even in
physiological media, MTAP-deleted cells secrete MTA. We also
investigated the effects of culture medium on SDMA levels of
MTAP-deleted and WT glioma cells (Supplementary Fig. 10f). No
significant difference was observed in the SDMA levels of MTAP-
deleted cells cultured in DMEM versus physiological media, with
MTAP-deleted cells having lower SDMA levels. Our findings
indicate that MTAP-deleted cells accumulate and extrude MTA
when grown in a nutritional environment similar to human
plasma, which would more accurately reflect the human situation.
However, we do not explicitly rule out the hypothesis that
nutrient differences (i.e., extremely low levels of cysteine11) may
contribute to the discrepant observation of lack of MTA accu-
mulation in primary human tumors with MTAP-deletion.
Another possible explanation could be the extrusion of MTA
out of the tumor into the circulation. To investigate this
possibility, we interrogated MTA levels in a metabolomic
profiling dataset of cerebrospinal fluid from GBM compared
and normal brain47. Given that the frequency of homozygous
MTAP deletions in GBM is around 50%, we would have expected
to observe a higher MTA level in the cerebrospinal fluid from at
least some GBM compared to the normal brain (Supplementary
Fig. 11a, b). However, the difference in MTA levels between
cerebrospinal fluid from GBM versus normal brain was
nonsignificant, with no significant individual outliers. To
corroborate the low likelihood of significant MTA secretion into
the circulation, we compared MTA levels between venous and
arterial plasma downstream and upstream of the glioma, as well
as plasma obtained from a dorsal pedal vein of the same patient,
control (Supplementary Fig. 11c–e; data obtained from Supple-
mentary Information of Xiong et al.48). Metabolites secreted by
tumors are carried downstream by venous blood, resulting in high
levels of that metabolite in glioma venous compared to arterial
plasma. While there were few GBM tumors in this study, given
the high frequency of homozygous MTAP deletion in GBM, it is
very likely that one or two GBM tumors to be homozygous
MTAP-deleted in this dataset. The GBM tumor 5P had the
highest MTA ratio of glioma venous to arterial. However, for the
same patient, the MTA ratio of the dorsal pedal vein (control) to
glioma arterial plasma was also high (Supplementary Fig. 11d),
indicating high MTA production in the patient’s leg. Finally, as
shown in Supplementary Fig. 11e, no GBM tumor had a
significantly higher ratio of MTA in the dorsal pedal vein versus
glioma venous plasma than low-grade glioma. These findings
indicate that MTA’s secretion out of the tumor into the
circulation is not a significant contributor to the discrepancy in
the MTA levels between homozygous MTAP-deleted human
GBM tumors and cells in culture.
It is already well-established that GBM tumors may have up to
75% (range 25–75%) non-malignant stromal cells, including non-
transformed reactive astrocytes, microglia, macrophages, neutro-
phils, lymphocytes, endothelial cells, fibroblasts, and axonal and
neuronal remnants30,31,49–51. Thus, a homozygousMTAP-deleted
GBM tumor is an admixture of non-malignant MTAP-expressing
stroma and MTAP-null malignant glioma cells. To verify the
diagnosis of homozygous MTAP deletion and contrast this status
with the extensive MTAP expression levels in non-malignant
tissue, we performed immunohistochemistry on intracranial
xenografted gliomas in mice. We first validated an MTAP rabbit
monoclonal antibody by demonstrating intense staining in
formalin-fixed paraffin-embedded (FFPE) sections of MTAP-
WT tumors and loss of staining in MTAP-deleted tumors gener-
ated from known MTAP-genotype cell lines (Supplementary
Figs. 12–14). Every xenograft established from MTAP-WT (or
isogenic MTAP-rescued) cancer cell lines showed intense
staining, while all xenografts established from MTAP-deleted cell
lines showed no staining. Simultaneously, non-malignant stromal
cells such as microglia, lymphocytes, and endothelial cells stained
positive for MTAP. Together, these staining results support that
this antibody accurately quantifies MTAP levels in FFPE slides.
Notable among our stained slides was the significant amount of
positive staining in the normal mouse brain and stromal cells,
especially given that xenografts typically grow much less
invasively and are less populated by stromal cells compared to
human GBMs (Supplementary Fig. 15). By extension, true human
GBMs are more likely to contain a higher proportion of stromal
components such as astrocytes and myeloid cells.
Next, we applied this antibody to FFPE primary GBM sections.
Of the 60 cases analyzed, we found that approximately 40% of
cases showed a complete lack of MTAP staining in cancer cells,
which generally corresponds to the expected MTAP-deleted
frequency in GBM41; notably, intense staining was observed in
non-malignant stromal cells. MTAP-intact cases showed intense,
uniform staining in both glioma and stromal cells (Fig. 3,
Supplementary Fig. 17). The histology of MTAP-deleted primary
GBM cases appeared similar to the MTAP-deleted intracranial
xenografted cases, except that the degree of MTAP-positive
stromal infiltration was much more significant in the primary
human GBM tumors compared to xenografts (Supplementary
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Fig. 15). Supplementary Fig. 16a–c shows the strong correlation
between the residual MTAP staining and myeloid content in
MTAP-deleted GBM tumors. In homozygous MTAP-deleted
tumors, the residual MTAP staining is restricted to stromal cells
(no MTAP staining in malignant glioma cells), predominantly of
myeloid origin (IBA1-positive). We also interrogate an indepen-
dent dataset (TCGA41) for the correlation between mRNA levels
of MTAP and AIF1 (the official gene symbol of IBA1, microglia/
macrophages marker) among GBM tumors with known MTAP
status. Supplementary Fig. 16d indicates a significant positive
correlation between mRNA levels of MTAP and AIF1 in MTAP-
deleted tumors versus intact ones. However, no positive
correlation was observed between MTAP and AIF in MTAP-
intact tumors since both glioma and stromal cells express MTAP
in MTAP-intact tumors. This figure also indicates that homo-
zygous MTAP-deleted GBM tumors, on average, have lower but
non-zero levels of MTAP mRNA levels compared to MTAP-
intact tumors, supporting our western blot data in Fig. 2g, h and
validate that IBA1-positive myeloid cells drive the non-zero
MTAP expression in bulk MTAP-deleted GBM tumors.
Fig. 3 Primary GBM tumors are extensively infiltrated by MTAP-expressing non-malignant stromal cells. a Immunohistochemistry (IHC) for MTAP and
IBA1 on formalin-fixed paraffin-embedded (FFPE) sections of GBM tumors. b, c IHC was performed with monoclonal anti-MTAP. The slides were developed
with EnzMet (black staining indicates MTAP expression) and counterstained with hematoxylin (blue, nuclei) and eosin (pink, cytosol, and extracellular
space) on at least 50 cases stained with MTAP and IBA1 and representative of three independent cases are shown. Representative sections of MTAP-
positive (b) and an MTAP-negative GBM tumor (c); x20 objective. Note the extensive MTAP-positive staining areas on the background of otherwise non-
staining MTAP-negative glioma cells; histopathologic evaluation of morphology indicates that these MTAP-positive cells correspond to stromal
components, including microglia, endothelial cells, and activated astrocytes. d Higher magnification view of c golden square. Any MTA secreted by MTAP-
deleted glioma cells (blue dashed outline) stands to be phosphorylated by MTAP (producing 5-MTR-P) either released or taken up by MTAP-expressing
stromal cells (white dashed outlines). e A representative section of an MTAP-negative GBM tumor stained against IBA1 antibody (myeloid marker),
indicating the extensive presence of myeloid cells (microglia/macrophages) inside GBM tumors. f Higher-magnification view of e.
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Having identified MTAP-WT cells’ presence (i.e., stromal cells,
which are predominantly myeloid in GBM) inside MTAP-deleted
tumors, we hypothesized that excess MTA secreted from
homozygous MTAP-deleted cancer cells may be metabolized by
non-malignant MTAP-expressing cells present inside tumors. To
test this hypothesis, we cultured MTAP-WT macrophages with
exogenous MTA and measured MTA levels in conditioned media
using proton NMR (1H-NMR). In the Supplementary Fig. 18a, b,
no MTA peaks were detected from the conditioned media of
MTAP-WT macrophages (RAW-264.7 and MV-4-11) incubated
with exogenous MTA compared to media from a control plate
(DMEM) or conditioned media fromMTAP-deleted leukemia cells
(CCRF-CEM) under the same experimental condition. This result
indicates that either MTAP-WT cells release functional MTAP
enzyme into the media or take up MTA from the media and
metabolize it. First, we sought to see whether the release of
functional MTAP enzyme by MTAP-WT cells is responsible for
eliminating exogenous MTA from conditioned media. We grew
MTAP-WT RAW-264.7 (macrophages) cells in DMEM; after
3 days, we collected the conditioned media and spun it down to
remove any cells, then we incubated the conditioned media
collected from RAW-264.7 cells with 20 μM exogenous MTA for 3
more days. Supplementary Fig. 19a shows that exogenous MTA
was not eliminated from the cell-free conditioned media from
macrophages. This result indicates that the release of functional
MTAP enzymes does not contribute to the disappearance of
exogenous MTA from the conditioned media of MTAP-WT cells.
Next, we sought to investigate whether exogenous MTA is taken
up and metabolized by MTAP-WT cells. Thus, we cultured
MTAP-WT macrophages (RAW-264.7) or glioma cells (D423)
with labeled methyl tri-deuterated-MTA (D3-MTA) (Fig. 4a). We
observed rapid elimination of labeled D3-MTA from the condi-
tioned media of MTAP-WT cells followed by deuterium enrich-
ment of intracellular MTA, methionine, and SAM (Fig. 4b, c, and
Supplementary Fig. 19c, d). Figure 4d shows the deuterium’s fate
from the labeled D3-MTA into methionine (methionine salvage
pathway) and SAM (polyamine biosynthesis). This result indicates
that extracellular MTA can be taken up and metabolized by
MTAP-WT cells.
Next, we co-cultured MTAP-deleted glioma cells with macro-
phages (RAW-264.7), immortalized normal human astrocytes,
and isogenic MTAP-rescued cells (U87-MTAP) and measured
MTA levels in conditioned media using 1H-NMR. We observed
robust accumulation of MTA in the conditioned media ofMTAP-
deleted cells but not of MTAP-WT or MTAP-rescued cells
(Fig. 4e). When MTAP-deleted U87, SW1080, HT1080, and
SKMEL5 cells were co-cultured with MTAP-WT macrophages
(Fig. 4e) or normal human astrocytes (Supplementary Fig. 18c),
no MTA peaks were detected in the conditioned media by 1H-
NMR. Furthermore, the co-culture of U87 parental MTAP-
deleted glioma cells with U87 MTAP-rescued cells resulted in the
disappearance of MTA peaks in the 1H-NMR spectrum of the
conditioned media (Supplementary Fig. 20). These results
indicate that secreted MTA from MTAP-deleted cells is
consumed (metabolized) by MTAP-WT cells; thus, co-culture
of MTAP-deleted with MTAP-WT cell lines abrogates MTA
accumulation in conditioned media. We also confirmed secretion
and consumption of MTA when MTAP-deleted cells are co-
cultured with macrophages in physiological media (Plasmax,
Supplementary Fig. 18d). Our findings indicate that MTAP-
WT cells in the vicinity of MTAP-deleted cancer cells prevent
extracellular accumulation of MTA.
We also investigated the effects of co-culturing MTAP-deleted
and MTAP-intact cells on PRMT5 activity—intracellular MTA
levels—of MTAP-deleted cells. We earlier discussed the dis-
crepancies in the magnitudes of reported MTA between MTAP-
deleted andMTAP-WT cancer cell lines. To avoid such problems,
we used a different approach to assess MTA levels inside cells
indirectly. Since intracellular MTA inhibits PRMT5 activity and
subsequently decreases SDMA levels, assessing SDMA levels by
western blot is an indirect measurement of intracellular MTA.
MTAP-deleted and MTAP-rescued cells were co-cultured with
suspended leukemia MV-4-11 (monomyelocytic leukemia,
macrophage-like) cells in DMEM. After 3 days, suspended
leukemia cells were removed, and adherent cells were washed
twice with phosphate-buffered saline (PBS) before they were
lysed. On western blot (Fig. 4f), monoculture MTAP-deleted cells
had lower SDMA levels, indicating lower PRMT5 activity and
higher intracellular MTA levels than co-cultured MTAP-deleted
cells. These findings emphasize that the co-culture of MTAP-
deleted cells with MTAP-intact cells negates the selective
vulnerability caused by MTAP deletion, thereby indicating that
MTAP-deletion sensitivity in a heterogeneous human GBM
tumor may be attenuated by the presence of stroma in the tumor
microenvironment.
Discussion
We undertook this study in response to the emergence of
homozygous MTAP-deleted precision therapy endeavors despite
a lack of exploration of the metabolic state of primary tumors. As
the therapeutic window of therapies directed at MTAP deletion
relies on massive intracellular accumulation of MTA9,10,15,52–54,
ensuring that this in vitro phenotype is consistent in human
tumors was a natural and urgent area for investigation. Perhaps
surprisingly, none of the recent papers documenting MTAP-
dependent vulnerabilities reported MTA measurements in pri-
mary human tumors or even xenografted tumors of defined
MTAP-deletion status, despite the significant efforts that have
been built on the supposition that observed elevations in MTA
in vitro would be reflected in primary tumors9,10,15,52–54.
We took to the literature—keen on finding studies describing
MTA levels in distinct, genetically defined homozygous MTAP-
deleted primary tumors—but with little success. We could not
find any literature reports directly measuring MTA levels in
genomically identified MTAP-deleted than MTAP-intact primary
human tumors, whether GBM or others. This was quite sur-
prising, given that MTA is a metabolite frequently detected in
many metabolomic profiling studies.
To fill this gap, we interrogated our metabolomic datasets
generated from different sets of GBM tumors using two inde-
pendent metabolic platforms (BIDMC and Metabolon, Inc.). Our
data suggest a statistically insignificant increase in MTA levels
between homozygous MTAP-deleted and MTAP-intact tumors.
This marginal elevation in MTA levels was at odds with the vast
elevations in MTA reported for MTAP-deleted cell lines
in vitro9,10,15. To investigate whether the in vitro metabolic vul-
nerability posed byMTAP deletion holds in human GBM tumors,
we assessed PRMT5 activity by measuring SDMA levels in the
same set of human tumors in which we performed metabolomics.
Unlike in cell culture experiments, we did not observe lower
SDMA levels in homozygous MTAP-deleted tumors compared to
intact ones. As an independent verification of our findings, we
queried the public domain datasets of metabolomic studies per-
formed on human GBM tumors33,44. We did not observe statis-
tically significant MTA elevation in GBM tumors with low MTAP
expression compared to those with high MTAP expression or
GBM tumors with frequent MTAP deletions and grade 2 and 3
glioma tumors with rare MTAP deletions. If MTAP deletions do
indeed lead to MTA accumulation in primary human tumors, we
would expect to observe dramatically higher MTA levels (on the
order of >20-fold, as seen in in vitro intracellular data from
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Fig. 3c in that publication9) in a substantial fraction of GBM
tumors. Our study evaluated MTA in bulk GBM tumors, which
are a heterogeneous mixture of cancer and stromal cells. One
shortcoming of performing metabolomics and western blots on
such tumors is that the measured signal (i.e., MTA levels and
SDMA levels) derived from both cancer and stromal cells.
Although signal derived from cancer cells is diluted by stromal
cells, significant metabolic aberrations such as elevation of 2-HG
can still be seen in resected bulk tumors (Fig. 2f and Supple-
mentary Fig. 7). However, our data of profiling GBM tumors
from two different dataset (HF series and MDA series) demon-
strate that there are nonsignificant 1.4-fold (p= 0.2) and 1.14-
fold (p= 0.9) increase in MTA levels in MTAP-deleted tumors
versus intact ones. These numbers are too low to be explained by
signal dilution caused by stromal contamination if cell culture
data are taken as a reference point. However, our data do not rule
the possibility of minor accumulation of MTA in MTAP-deleted
glioma cells; just that such accumulation would have to be much
less than reported in culture.
In sum, the extreme elevation of MTA in homozygous MTAP-
deleted cells in vitro did not extend to our metabolome analyses
of primary GBM tumors. A variety of reasons may explain this
discrepancy between cell culture and human tumor data. The
explanation we favor centers on the observation that MTAP-
deleted cells excrete MTA into the media (Fig. 1h). In the lit-
erature, we noticed large discrepancies between different studies
Fig. 4 Exogenous MTA is consumed by MTAP-intact cells through the methionine salvage pathway. a MTAP-WT macrophages (RAW-264.7) were
cultured with 100 µM methyl tri-deuterated-MTA (D3-MTA). Cells and conditioned media were extracted and prepared for LC-MS and NMR
measurements, respectively. b Exogenous D3-MTA rapidly disappears from the media in cultures of macrophages, as the deuterium label (Mass+ 3; M+
3) appears in intracellular methionine and SAM (c), consistent with MTAP-dependent metabolism by the methionine salvage pathway (d). Data in panel c
are expressed as mean+ SD, N= 3 biological replicates. e MTAP-deleted cancer cells accumulate MTA in conditioned media (detected by NMR) while
secreted MTA is consumed by MTAP-intact macrophages, abrogating MTA accumulation in the extracellular environment. f Co-culture of MTAP-deleted
cancer cell lines with MTAP-intact myeloid cells prevents loss of SDMA, indicating maintained PRMT5 activity, repeated once. MTAP-deleted and
reconstituted glioma cells were co-cultured with myeloid leukemia cells (MV-4-11, a monomyelocytic suspension cell line). Before lysate preparation,
suspended MV-4-11 myeloid cells were removed, and cancer cells were extensively washed. For each independent MTAP-deleted cell line, SDMA levels
increased with myeloid co-culture, indicating restoration of PRMT5 activity.
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in the magnitudes of reported MTA increases in MTAP-deleted
versus MTAP-intact cancer cell lines (Supplementary Fig. 2).
Careful analysis of these results in light of our own in vitro data
points to MTA secretion out of homozygous MTAP-deleted cells.
Thus, the discrepancies between different studies appear to arise
from how well intracellular and extracellular metabolite levels are
differentiated during sample processing. Secretion of MTA by
MTAP-deleted cells in agreement with previous studies19,55 fur-
ther corroborate this finding.
An additional explanation suggested by our findings is that
human GBM tumor environments are extensively infiltrated by
MTAP-expressing non-malignant stromal cells (Fig. 3 and Sup-
plementary Figs. 15 and 16). To investigate the effects of MTAP-
WT cells in the vicinity of MTAP-deleted cells on intracellular
and extracellular MTA levels, we co-cultured MTAP-deleted cells
with MTAP-WT ones. We observed that this co-culture abro-
gated the accumulation of MTA in the conditioned media of
MTAP-deleted cells. Furthermore, we found that the co-culture of
MTAP-deleted cells with suspended MTAP-WT leukemia cells
(MV-4-11, myeloid-like) resulted in higher SDMA levels—indi-
cating higher PRMT5 activity and lower intracellular MTA levels
—compared to the monoculture MTAP-deleted cells. Also, cul-
turingMTAP-WT cells with labeled D3-MTA revealed labeling of
intracellular MTA, methionine, and SAM, evidencing MTA
uptake, consumption, and metabolism by MTAP-WT cells. These
findings suggest that the metabolism of MTA by stromal cells is
likely the predominant cause of the absence of any detectable
increase in MTA in primary GBMs. However, our study does not
rule out other factors that could influence MTA accumulation in
MTAP-deleted cells, i.e., extreme cysteine deficiency shown by
Sanderson et al.11 (though physiological media Plasmax still
yielded MTA secretion in MTAP-deleted glioma cells, Supple-
mentary Fig. 10). Our findings highlight the metabolic dis-
crepancies between in vitro models and primary human tumors.
It is already well understood that cell culture conditions do not
always accurately reflect physiologic, metabolic conditions11,56,57:
our study exemplifies another aspect, stromal infiltration, as a
complicating factor for tumor metabolism. Our results suggest
more systematic efforts to validate cell culture and xenograft
studies on cancer metabolism with primary human tumor data.
That MTAP deletions can be leveraged as a point of selective
vulnerability in various cancers has spurred much excitement.
Our analysis challenges whether the metabolic conditions
required for therapies to exploit vulnerabilities associated with
elevated MTA/MTAP deletions are present in primary human
tumors, giving pause to whether these would translate to the
clinic. However, our findings do not rule out that MAT2A and/or
PRMT5 inhibitors could prove useful in oncology. Merely, such
inhibitors would have to achieve a therapeutic window through a
mechanism other than MTA accumulation. Indeed, recent
research has already pointed towardMTAP-deletion-independent
sensitization mechanism to PRMT5 inhibition58. Some GBM
tumors in our dataset showed relatively low SDMA levels—sug-
gesting low PRMT5 activity—without MTAP deletions (Fig. 2g).
Perhaps such tumors with low PRMT5 activity could be suitable
candidates for targeted therapies against PRMT5 or MAT2A,
provided a reliable molecular marker can be found to
identify them.
Methods
Identification of cell lines with MTAP-homozygous deletions. Scoring of
homozygous deletions, even with robust copy-number data, can be problematic
owing to uneven ploidy across cell lines, as well as where deletion boundaries only
partially cover the gene yet eliminate its functional expression. Thus, we sought to
identify functionally MTAP-null cell lines. For the NCI-60 cell line comparisons,
we gathered data from the Sanger Center Catalogue of Somatic Mutations in
Cancer59. We used confirmed data from cBioPortal with the NCI-60 panel
data43,60 and DepMap from the Cancer Cell Line Encyclopedia and the Genentech
collection61. Where deletion calls were ambiguous (e.g., SF-295), we looked at
mRNA expression data or literature western blot data9,10,15,52 to decide what
constituted a functionally MTAP-null cell line. In the NCI-60 cell line panel, the
following cell lines lack MTAP: NCI-H322, SKMEL5, K562, SF268, MALME3M,
ACHN, MDAMB231, OVCAR5, CCRF-CEM, SR, MCF7, and A549.
Cell culture and xenograft generation. The cell lines used in this study that are
MTAP-WT were D423 (CVCL_1160, H423/D423-MG) and D502 (CVCL_1162,
H50262), which were kindly provided by Darrel Bigner62. U343 (CVCL_S471,
U343-MG63), LN319 (CVCL_3958, a sub-clone of LN-99264), and NB1
(CVCL_1440) were obtained from the Department of Genomic Medicine/Institute
for Applied Cancer Science Cell Bank at MD Anderson. MV-4-11 (CVCL_0064)
was purchased from NCI, RAW-264.7 (CVCL_0493) was purchased from ATCC
(TIB-71), and immortalized normal human astrocytes was kindly provided by Dr.
Seth Gammon (Cancer System Imaging. The MTAP-deleted cell lines U87 (CVCL-
0022), SW1088 (CVCL_1715), and SKMEL5 (CVCL_0527) were obtained from the
Department of Genomic Medicine/Institute for Applied Cancer Science Cell Bank
at MD Anderson. Gli56 (D. Louis) and CCRF-CEM (CVCL_0207) were purchased
from NCI. HT1080 (CVCL_0317) was kindly provided by Dr. Seth Gammon
(Cancer Systems Imaging). All cell culture experiments were conducted according
to the provider’s instructions and as previously described65. The U87 MTAP-
rescued cell line was generated using the same procedure we previously used to
generate an ENO1-rescued cell line1. The MTAP cDNA was obtained from Life
Technologies, sequence-verified, and cloned into a pCMV GFP lentiviral vector
using Gateway cloning technology. 293T cells were transfected with viral plasmids
using polyethyleneimine. The viral supernatant was collected 72 h after transfection
and added to the U87 cell line for infection.
All cells were cultured at 37 °C in a 5% CO2 atmosphere at pH 7.4 in ATCC-
suggested media (DMEM) unless stated otherwise. DMEM has 4.5 g/l glucose,
pyruvate and glutamine (Cellgro/Corning, #10-013-CV) with 10% (20% for Gli56)
fetal bovine serum (Gibco/Life Technologies, #16140-071), 1%
penicillin–streptomycin (Gibco/Life Technologies, #15140-122), and 0.1%
amphotericin B (Gibco/Life Technologies, #15290-018). All cell lines were
confirmed as mycoplasma negative by enzyme-linked immunosorbent assay using
the MycoAlert PLUS Detection Kit (Lonza) and were authenticated by short
tandem repeat DNA fingerprinting and chromosomal analysis by the Cytogenetics
and Cell Authentication Core at MD Anderson.
MD Andersons’s Institutional Animal Care and Use Committee approved all
procedures for animal studies. Xenografts with the D423 (MTAP-WT), U87
(MTAP-deleted), U87 pCMV MTAP (MTAP-rescued), NB1 (MTAP-WT),
SKMEL5 (MTAP-deleted), and Gli56 (MTAP-deleted) cancer cell lines were
generated as detailed below for FFPE sections. For subcutaneous xenografts, 5
million cells were injected in the flanks of a nude athymic mouse (bred by MD
Anderson’s Department of Experimental Radiation Oncology). Mice were housed
in a room with an ambient temperature between 20 and 22 °C and humidity of
30–70%, in a 12-h light–12-h dark cycle. Tumors were harvested and fixed in 4%
phosphate-buffered formalin. Dehydration, paraffin embedding, and tissue
sectioning were performed by MD Anderson’s Veterinary Pathology Core.
Intracranial glioma cell injections were performed by the MD Anderson
Intracranial Injection Core at MD Anderson (Dr. Fred Lang, Director66).
Immunocompromised female nude Foxn1nu/nu mice were first bolted. After
2 weeks, the mice were injected with 200,000 cells into the brain through the bolt
by the MD Anderson Intracranial Injection Fee-for-Service Core66. Formalin-fixed
brains with xenografted glioma tumors were submitted to the Veterinary Pathology
Core for embedding and sectioning.
Metabolomic profiling of polar metabolites. Polar metabolites were profiled
using the BIDMC platform. The extraction of samples was performed in the house
as follows for each specific set of samples. Polar metabolites of GBM tumors were
also profiled through fee for service by Metabolon, Inc. (Durham, NC).
Targeted MS. A hybrid QTRAP 5500 triple quadrupole mass spectrometer (AB
SCIEX), which is coupled to a Prominence UFLC HPLC system (Shimadzu), was
used. First, each sample was resuspended in 20 μl high-performance liquid chro-
matography (HPLC)-grade water, then 5–7 μl of it was injected into the spectro-
meter. The selected reaction monitoring (SRM) method was used for steady-state
analyses with 262 endogenous water-soluble metabolites with a dwell time of 3 ms
for each SRM, and a total cycle time of 1.55 s, with 10–14 data points acquired for
each metabolite. Voltages used for the positive and negative ion modes were +4950
and −4500 V, respectively. Hydrophilic interaction chromatography using a
4.6 mm × 10 cm Amide XBridge column (Waters) at 400 μl/min was used to deliver
samples to the spectrometer. Following gradient sequence were used during the
measurement: 85% buffer B (HPLC grade acetonitrile) to 42% B from 0 to 5 min,
followed by 42% B to 0% B from 5 to 16 min, with no gradient from 16 to 24 min,
and finally, gradients were run from 0% B to 85% B from 24 to 25 min, and 85% B
was held for 7 min to re-equilibrate the column. Buffer A comprised 20 mM
ammonium hydroxide/20 mM ammonium acetate (pH 9.0) in 95:5 water:
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acetonitrile. MultiQuant v2.1 software (AB SCIEX) was used to integrate total ion
current peak.
Intracellular metabolites from cells in culture (cell pellet). Adherent cancer
cells growing in 10-cm plates at 50–90% confluency were harvested for metabo-
lomic profiling as follows. First, media was removed (and extracted for its profil-
ing), and the plated cells were washed twice with ice-cold 1× PBS (Corning). Cells
were then placed in dry ice, and we added 4 ml of 80% methanol pre-cooled to
−80 °C. Then they were incubated in the −80 °C freezer for 20 min. Cells were
scraped off the plate while on dry ice, placed in pre-cooled tubes, and finally
centrifuged at maximum speed, 17,000 × g for 5 min at 4 °C. The supernatant
containing polar metabolites was concentrated using an Eppendorf Vacufuge
Plus67 and submitted to the BIDMC MS core.
Secreted metabolites (conditioned media). A total of 1–2 ml of conditioned
media was centrifuged at maximum speed for 10 min to remove any unblocked
cells or cell debris. Subsequently, 4 volumes of −80 °C pre-cooled methanol for
every 1 volume of media was added to make the final concentration of 80%
(vol/vol) methanol solution, then vortexed and left at −80 °C for 6–8 h to pre-
cipitate serum and extract polar metabolites. Ice-cold methanol media mix was
centrifuged at maximum speed (17,000 × g) for 10 min at 4 °C. Following cen-
trifugation, the supernatant was separated and dried in the vacuum concentrator
(Eppendorf Vacufuge Plus) and then sent to the BIDMC core67.
Frozen tumors. GBM tumors were collected under the protocol approved by the
institutional review board at MD Anderson Cancer Center (PA15-0940, LAB03-
0320, and LAB03-0221). Under the protocol, informed written consent from
patients was obtained. Tumors snap-frozen in liquid nitrogen were kept at −80 °C
until extraction and never thawed. Every effort was taken to keep tumors frozen
until they were placed in cold methanol. Frozen tumors were weighed on dry ice
without thawing, and we placed them in dry ice pre-cooled Fisher Tube (#02-681-
291) with Qiagen steel beads. Then we added 1 ml of 80% at −80 °C pre-cooled
methanol to each tube. Then we shook the tubes with Qiagen TissueLyser for 45 s
at room temperature at 28 Hz for multiple rounds. We placed the tubes in the dry
ice between each round. After samples became homogenous, the samples’ final
volume was proportioned to 50 mg of tissue/2 ml of 80% methanol. After this step,
we kept the samples at −80 °C for 24 h and then vortexed each sample and cen-
trifuged them at maximum speed (17,000 × g) for 10 min at 4 °C. Then we collected
the supernatant and stored it at −80 °C until vacuum concentration. For each
study, we used Eppendorf Vacufuge Plus to vacuum-concentrate the same volume
of samples. Dried samples were sent to the BIDMC core.
Determination of MTA by 1H-NMR in conditioned cell culture media. Condi-
tioned media from cells was collected and centrifuged for 10 min to remove cells
and cell debris. Post-centrifugation media (2 ml) was transferred to a new tube,
where 4 (8 ml) volumes of methanol were added to precipitate proteins. The
sample was then vortexed and centrifuged at the highest speed for 10 min, and the
supernatant was transferred to a new tube. The post-centrifuged supernatant (8 ml)
was then vacuum concentrated using the Eppendorf Vacufuge Plus followed by
lyophilization for 24 h; the resulting pellet was resuspended in 600 μl of D-DMSO
(dimethyl sulfoxide-d6; Alfa Aesar, 99.5%, #A16893-18). Any insoluble material
was removed by centrifugation. The clear D-DMSO solution was then placed in a
5-mm NMR tube for NMR analysis. 1H-NMR measurements were performed on a
Bruker Avance III HD 500MHz equipped with a CryoProbe Broadband Observe
probe or a Bruker Avance One 600MHz equipped with a 5-mm TXI probe at MD
Anderson Cancer Center. The resulting spectrum was obtained using the zg30
pulse sequence with either 100 or 1024 scans and a relaxation delay equal to 1 s.
Spectrum analysis was performed using the Bruker TopSpin 3.1 software. For
MTA, the adenosine protons (HMDB0001173), with chemical shifts of 8.15 and
8.35 ppm, were readily detectable in the supernatant of MTAP-deleted media
extract, but not MTAP-intact or MTAP-rescued extract, and in the supernatant of
co-cultured MTAP-deleted and MTAP-intact media extract. The most intense
MTA peak occurred at 2.1 ppm, corresponding to the methyl group protons
adjacent to the sulfur. However, in the media extract of MTAP-deleted cells, this
peak was obscured by more abundant metabolites. The peaks for the ribose group
were of low intensity and not detectable. We validated our observed chemical
shifts by spiking sample extracts with pure MTA standard (Sigma-Aldrich,
#D5011, 100 mg).
Absolute quantification of MTA in the cell pellet and the conditioned media.
MTAP-deleted and WT cells were grown in DMEM or Plasmax supplemented with
2.5% FBS. After 3 days, the cell pellet and the conditioned media were harvested for
quantification of MTA. Media was collected, spun down to remove any cells, and
extracted with 80% methanol. Cells were washed with ice-cold 1× PBS (Corning)
and placed in dry ice. Two hundred microliters of the extraction buffer (40%
methanol: 40% acetonitrile: 20% water) pre-cooled to −20 °C. Cells were scraped
off the plate while on dry ice placed in pre-cooled tubes. The concentration of
MTA in the extract of cell pellet and extract of media was determined in LC-MS. A
quadrupole-orbitrap mass spectrometer (Q Exactive, Thermo Fisher Scientific, San
Jose, CA) coupled to hydrophilic interaction chromatography was used for MTA
quantification. LC separation was on an XBridge BEH Amide column (2.1 mm ×
150mm × 2.5 mm particle size, Waters, Milford, MA) using a gradient of solvent A
(20 mM ammonia acetate, 20 mM ammonium hydroxide in 95:5 water: acetoni-
trile, pH 9.45) and solvent B (acetonitrile). The flow rate was 150 µl/min. LC
gradient was: 0 min, 85% B; 2 min, 85% B; 3 min 80% B; 5 min, 80% B; 6 min, 75%
B; 7 min, 75% B; 8 min, 70% B; 9 min, 70% B; 10 min, 50% B; 12 min 50% B; 13
min, 25% B; 16 min, 25% B; 18 min, 0% B; 23 min, 0% B; 24 min, 85% B. MS scans
were performed from m/z 70–1000 at 140,000 resolution. For MTA quantification,
deuterium-labeled MTA was used as an internal standard. Data were analyzed
using the EI-Maven 7.0 software (Elucidata, LLC., elucidata.io.), and isotope
labeling was corrected for the natural abundance. The absolute amount of MTA in
the total cell pellet and media (cell pellet approximately 3 M cells, media 3 ml) was
calculated from this concentration. The cell density was determined by harvesting
cells with trypsin and counting cells using trypan blue.
Tracing deuterated MTA. MTAP-WT mouse macrophages (RAW-267.4) and
glioma cells (D423) were cultured in a 6-well plate with and without 100 μM
deuterated MTA in DMEM for 1 day. Then cell culture media were collected and
prepared for NMR studies. Cells were washed with ice-cold 1× PBS (Corning) and
placed in dry ice. We then added 200 mM of the extraction buffer (40% methanol:
40% acetonitrile: 20% water) pre-cooled to −20 °C. Cells were scraped off the plate
while on dry ice placed in pre-cooled tubes and finally centrifuged.
Validation of an anti-MTAP rabbit monoclonal antibody for the immunohis-
tochemistry. To confirm homozygous deletions MTAP by immunohistochemistry
in primary tumor FFPE sections, we first validated a monoclonal antibody for this
application by demonstrating staining in FFPE slides of xenografted tumors with a
known MTAP genotype. Xenografts generated with the D423 (MTAP-WT), U87
(MTAP-deleted), U87 pCMV MTAP (MTAP-rescued) NB1 (MTAP-WT),
SKMEL5 (MTAP-deleted), and Gli56 (MTAP-deleted) cancer cell lines were fixed
in formalin and embedded in paraffin. Immunohistochemistry was performed on
coronal sections of mouse brain xenografted with human glioblastoma cells. Tissue
was fixed in formaldehyde before being embedded in paraffin. The tissue was sliced
to the desired thickness and embedded onto the slide. Slides were left to incubate at
60 °C overnight. To detect MTAP, sections were subjected to antigen retrieval in
citrate buffer (1:100 Vector Laboratories Antigen Unmasking Solution [Citrate-
Based], H-3300, 250 ml) at high pressure for 10 min. Sections were covered with a
blocking buffer of 2% goat serum (Vector Laboratories, S-1000, Normal Goat
Serum, 20 ml) in PBS (Quality Biological PBS 10×, pH 7.4, 1000 ml) for 1 h. Sec-
tions were then covered with anti-MTAP rabbit monoclonal (Abcam, #ab126623,
clone EPR6892, Lot: GR97816-5, Lot: YI070108C5) in a 1:200 dilution with 2%
goat serum in PBS and left to incubate overnight at 4 °C. Sections were then washed
in PBS and incubated for 30 min with 1× goat anti-rabbit IgG secondary antibody,
poly-horseradish peroxidase conjugate (Invitrogen by Thermo Scientific, Ref:
B40962, Lot: 2140280). After being washed in PBS and Tween 20 (Fisher BioR-
eagents, #BP337-500), sections were developed using either Impact NOVAred
(Vector Laboratories; yields a red to brown color for stain) or using EnzMet
(Nanoprobes, #6001, 30 ml; yields a black stain). For NOVAred, slides were then
counterstained using hematoxylin; for EnzMet, slides were counterstained with
hematoxylin and, optionally, an eosin counterstain. Sections were mounted using
Denville Ultra Microscope Cover Glass (#M1100-02) and Thermo Scientific
Cytoseal 60 and left to dry overnight. There was an absolute correspondence
between the genotype of the xenografts and the MTAP staining by immunohis-
tochemistry, with only mouse stromal cells staining positive for MTAP in MTAP-
deleted xenografts (Supplementary Figs. 12–14). We thus proceeded to utilize this
antibody for scoring homozygous MTAP deletions in human primary GBM FFPE
sections. Immunohistochemistry was performed as described for the human
xenografted tumors. Immunohistochemistry was performed by utilizing citrate
antigen retrieval and blocking in 2% goat serum. Slides were stained against MTAP
(Abcam, rabbit monoclonal, #ab126623, Lot: GR97816-5, Lot: YI070108C5, Lot:
GR90092-13, overnight at 4 °C) in a 1:250 dilution and developed with 1× goat
anti-rabbit IgG secondary, poly-horseradish peroxidase conjugate (Thermo Sci-
entific, #B40962) for 30 min at room temperature and developed with NOVAred
(Vector Laboratories) or EnzMet (Nanoprobes, #6001, 30 ml) followed by coun-
terstaining with hematoxylin or hematoxylin and eosin. The same procedure was
used to stain the slides against the IBA1 antibody (Abcam, #ab178846, lot:
GR207976-27) in a 1:1000 dilution.
Western blot. Human snap-frozen GBM tumors were kept at −80 °C (same set of
tumors used for metabolomic study). Without thawing, approximately 10 mg of
tumor tissue was transferred to a new tube for immunoblotting. Lysates were made
in 200 μl of radioimmunoprecipitation assay buffer supplemented with protease
inhibitor (Roche, #11836153001) and phosphatase inhibitor (Roche,
#04906837001) followed by sonication at 4 °C. Protein quantitation was performed
via BCA assay (Pierce, #23225), and lysates were equilibrated for running on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a
polyvinylidene fluoride membrane. The following antibodies were used for this
study: SDMA motif (Cell Signaling Technology, #13222, Lot: 6) in a 1:1000
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dilution, MTAP (Abcam, #ab126623, Lot: GR97816-5, Lot: YI070108C5, Lot:
GR90092-13) in a 1:1000 dilution, GAPDH (Sigma-Aldrich, #G9545, lot:
127M4814V) in a 1:5000 dilution, IBA1 (Abcam, #ab178846, lot: GR207976-27) in
a 1:1000 dilution, and vinculin (Cell Signaling Technology, #13901) in a 1:5000
dilution. Western blot bands were quantified using ImageJ 1.52q.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Metabolomic data and uncropped scans of all blots are provided in the Source data file.
Raw NMR data in Fig. 4 and all metabolomic data are deposited in Figshare (https://doi.
org/10.6084/m9.figshare.14608002.v5). Data in Supplementary Fig. 11a, b with file name
011210QssCSF2HGnormGBM.txt are kindly shared by John Asara using the BIDMC
metabolomic platform, originally published in Locasale et al.47. Data in Supplementary
Figs. 6g and 16d obtained from cBioPortal42,43 (https://www.cbioportal.org) with source
data are available at http://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/
GBM/20160128/ and Brennan et al.41, respectively. Public domain metabolomic data
used in Supplementary Figs. 2a–c, 4a, 6, 7, 9, and 11c–e are available at Ortmayr el al.22,
Su et al.26, Dettmer et al.27, Kryukov et al.15, Prabhu et al.33, Chinnaiyan et al.44,
Sanderson et al.11, and Xiong et al.48, respectively. Raw NMR data used in Supplementary
Figs. 10e, 18, 19a, c, and 20 are available from the corresponding author upon reasonable
request. Source data are provided with this paper.
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